On 15 January 2025, Lexaria Bioscience announced that it has received independent ethics board approval to begin its first-ever human study of oral liraglutide, formulated from the DehydraTECH-processing of conventional injected liraglutide (Novo Nordisk’s Saxenda®).
The study is expected to involve 8-10 healthy volunteers and will compare the oral formulation with the conventional injected version. Lexaria considers this could potentially advance its DehydraTECH-processing technology as a leading drug delivery method. According to Lexaria, successful outcomes could lead to further clinical trials, potentially impacting the market for GLP-1 drugs significantly and providing new options for patients and healthcare providers.